Strategic Expansion to Enhance Women’s Health Care
Corona Remedies has successfully completed the construction of its latest manufacturing facility, dedicated to hormonal products, in Bhayla, Ahmedabad. Scheduled to start commercial production in the fiscal year 2026, this facility underscores Corona’s deep commitment to advancing women’s health care. The plant boasts an impressive capacity to produce 20 crore units annually, targeting both domestic and international markets.
The state-of-the-art facility will produce essential treatments for a variety of female health conditions, including dysmenorrhoea, polycystic ovary syndrome (PCOS), infertility, PMS, and other hormonal disorders. By focusing on these critical areas, Corona aims to address the growing demand for specialized women’s healthcare solutions.
Technological Innovation and Safety
Equipped with advanced isolator systems for handling potent hormonal Active Pharmaceutical Ingredients (APIs), the new facility is designed to ensure zero contamination and uphold the highest safety and quality standards. This integration of cutting-edge technology and stringent safety measures reflects Corona’s commitment to excellence and regulatory compliance.
Nirav Mehta, Managing Director & CEO of Corona Remedies, highlighted the importance of this initiative, stating, “The rapid growth of India’s women’s healthcare sector is driven by increased awareness and the rising prevalence of conditions such as PCOS, infertility, and hormonal imbalances. Despite women making up nearly half of the population, there has been a significant gap in specialized hormonal product manufacturing. Our new plant is set to bridge this gap, providing high-quality, reliable hormonal treatments.”
Leadership and Market Position
Corona Remedies continues to strengthen its market presence, holding a 4% share in the female hormone segment and maintaining leadership positions with key products like progesterone, dydrogesterone, and norethisterone. The addition of this new facility is expected to further solidify Corona’s position as a leader in the Indian pharmaceutical market and expand its impact on global healthcare solutions.
